Page 11234..1020..»

Category Archives: Ulcerative Colitis

Marvel Creates New Team of Superheroes Affected by IBD – IBD News Today

Posted: August 15, 2017 at 1:41 pm

Marvel Custom Solutions has partnered with Seb Tucknott, the founder of the online platform IBDRelief and pharmaceutical companyTakeda,to create a new team of superheroes who all have one thing in common:inflammatory bowel disease (IBD).

MORE:Sevenpeople with chronic illnesses who used a body-shaming experience to raise awareness

According to a report on metro.co.uk, the Unbeatables are allaffected by either Crohns disease or ulcerative colitis, along with an estimated onein 250 Britons. While fighting crime and protecting people around the world, the Unbeatables also pause to consider how their superhero actions may affect their IBD, including the impact of stress.

The team is made up of five characters:

Marvel has created a full graphic novel featuring the adventures of the Unbeatables to raise awareness of IBD. The first chapter was revealed at Londons Comic Con to more than 100,000 Marvel fans. The cover of the novel was created by Marvels Kirbi Fagan, an illustrator who also lives with Crohns disease.

MORE: Seven famous personalities with ulcerative colitis

IBD News Todayis strictly a news and information website about the disease. It does not provide medical advice,diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician orother qualified health providerwith any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

See the rest here:
Marvel Creates New Team of Superheroes Affected by IBD – IBD News Today

Posted in Ulcerative Colitis | Comments Off on Marvel Creates New Team of Superheroes Affected by IBD – IBD News Today

Ocean City to host Crohn’s, colitis 5k walk/run Sunday – Press of Atlantic City

Posted: at 1:41 pm

Several hundred people are expected to turn out in Ocean City this weekend in support of research and treatment for people with Crohns disease and ulcerative colitis.

Ocean City will host the Crohns and Colitis Foundations Guts and Glory 5k run and walk Sunday and organizers said they are expecting as many as 1,800 race participants.

Crohns and colitis are digestive diseases impacting more than 1.6 million American adults and children, according to the foundation.

Patients often experience a range of symptoms and flare-ups throughout their lives, including, but not limited to, weight loss, fatigue, internal tearing and bleeding and abdominal cramps.

There is no cure for Crohns disease, but doctors and other specialists are able to treat people in order to manage the condition with medications like corticosteroids, antibiotics and biological therapies.

Advocates and supporters can register for the race online up until 12 p.m. Saturday or in person Sunday from 7:30 to 8:25 a.m. before the race at the Aquatics and Fitness Center, 1735 Simpson Ave., Ocean City.

Pre-registered racers can pick up their event packets at the fitness center Saturday from 2:30 to 6 p.m.

This years race will spotlight its 2017 honored hero, Ashlynn Vanaria, of Moorestown, Burlington County, who was diagnosed with Crohns disease at 11 years old.

Vanaria and her family have supported the Guts and Glory 5k event for the past 10 years by advocating for support and raising money for the foundations causes. To date, they have raised more than $50,000 for Crohns and colitis treatment and research.

My family and I have spent the summers in Ocean City my entire life and learned about the Guts and Glory 5k two years after my diagnosis, Vanaria said in a statement. We look forward to this event all year. We will not give up, we will continue to fight and we will find cures.

Race participants are encouraged to donate money as individual entries or as a team. Supporters of participants can also make donations in the name of runners or walkers online. The event has raised, as of Monday, nearly $57,000.

The walk/run will begin at 8:30 a.m. at the fitness center and later include music, food and an awards ceremony. The events primary sponsor is Edmunds and Associates and will feature tables of local organizations and providers, including Shore Medical Center.

Go here to read the rest:
Ocean City to host Crohn’s, colitis 5k walk/run Sunday – Press of Atlantic City

Posted in Ulcerative Colitis | Comments Off on Ocean City to host Crohn’s, colitis 5k walk/run Sunday – Press of Atlantic City

Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial – IBD News Today

Posted: August 11, 2017 at 7:40 pm

Early data from a Phase 1b clinical trial show that the investigational therapy TD-1473 for patients with ulcerative colitis (UC) has demonstrated targeted action and effectiveness, according to the therapys developer and study sponsor,Theravance Biopharma.

Preliminary data are from four weeks of treatment. The ongoing study (NCT02818686), which currently is recruiting participants, is for patients with moderate to severe active UC.

TD-1473 is an orally administered, highly specific inhibitor of the Janus kinase (JAK) family of enzymes, which plays a key role in inflammation. Most importantly, TD-1473s activity is restricted to the intestinal tract, which prevents the risk of systemic exposure and unwanted side effects.

The study was designed to evaluatethe treatments safety, tolerability, and pharmacokinetics (a therapys behavior in the body) in UC patients during a 28-day period. Additional endpoints include assessing TD-1473s biologic effects by analyzing disease biomarkers and performing a thorough evaluation of clinical and endoscopic parameters.

In the exploratory study, 10 patients from the first cohort received 80 mg of TD-1473 once a day for 28 days, while a control group of three patients received a placebo.

Preliminary results from the first cohort revealed that TD-1473 induced a localized response (restricted to the intestine) with minimal systemic exposure. These results are similar to those observed in a Phase 1 study with healthy volunteers.

Treatment with TD-1473 was not associated with impairment to patients immune systems (immunosuppression), as they showed no differences in infections and the number of several key immune cells including leukocytes, neutrophils, and lymphocytes compared with placebo controls.

Some patients who received TD-1473 experienced improvements in several disease parameters, including a reduction in rectal bleeding and biomarkers for ulcerative colitis, such as serum C-reactive protein (CRP) and fecal calprotectin (FC), when compared with controls. Researchers also detected lower cytokine activity in tissue samples from treated patients and anoverall improvement inintestinal mucosal healing.

Treatment with TD-1473 resulted in no moderate or serious adverse events. Researchers observed only mild side effects, with none requiring study discontinuation.

The trial aims to recruit patients for two additional cohorts to evaluate TD-1473seffectiveness in three doses 80 mg, 20 mg, and 270 mg versus placebo-matched controls.

In a small Phase 1b trial not statistically powered to demonstrate efficacy, it is remarkable to see compelling directional change in local biological effect for patients receiving TD-1473, particularly a change in rectal bleeding and endoscopic subscores. Further, these effects were measured after just four weeks of treatment, a timeframe shorter than the typical induction endpoint in ulcerative colitis trials, William Sandborn, MD, chief of the University of California at San Diegos Gastroenterology Division, said in apress release. These early signals of efficacy with limited levels of systemic exposure position TD-1473 as a promising potential treatment for ulcerative colitis.

Brett Haumann, MD, Theravance Biopharmas chief medical officer, also was upbeat, saying, These data provide encouraging initial evidence of TD-1473s clinical activity in our first cohort of ulcerative colitis patients. In addition to seeing improvements in measurements of disease activity within four weeks of treatment, we have seen minimal systemic exposure and a favorable tolerability profile that is consistent with the desired target product profile.

Original post:
Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial – IBD News Today

Posted in Ulcerative Colitis | Comments Off on Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial – IBD News Today

Paediatric ulcerative colitis drug gets orphan designation – Drug Target Review

Posted: at 7:40 pm

The U.S. Food and Drug Administration has granted an orphan-drug designation to cobitolimod for the treatment of ulcerative colitis in pediatric patients

The U.S. Food and Drug Administration (FDA) has granted an orphan-drug designation to cobitolimod for the treatment of ulcerative colitis in paediatric patients.

We are pleased that the FDA has granted orphan-drug designation for cobitolimod for treatment of ulcerative colitis in children, which may provide seven years of market exclusivity in this indication on the US market, saidPeter Zerhouni, CEO of InDex Pharmaceuticals.

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favourable safety profile.

Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively.

Cobitolimod is also known as Kappaproct and DIMS0150.

Visit link:
Paediatric ulcerative colitis drug gets orphan designation – Drug Target Review

Posted in Ulcerative Colitis | Comments Off on Paediatric ulcerative colitis drug gets orphan designation – Drug Target Review

Crohn’s | Colitis | IBD | Crohns & Colitis Foundation

Posted: August 10, 2017 at 3:44 pm

GET INVOLVED

Summer is a great time to get involved with the Crohn’s & Colitis Foundation!

Join the Team Challenge Family — 10 years of racing for curesWhen you join the Team Challenge family,you’re supported by coaches, mentors, and friends who understand the impact of IBD. Join us this year at a 5k, 10k, half marathon, marathon, triathlon, IRONMAN, cycle event — or, turn anything else into a fundraiser when you Race in Orange. Learn more.

2017 spin4 crohn’s & colitis cures lineup just announced!It’s not too early to join the movement at one ofour 2017 spin4 crohn’s & colitis cures fall events. The time is now — grab some friends, reserve your bike, and join this fun indoor cycling relay! I want to #partyonabike!

Click on the arrow to select your state to find information on your local Chapter.

Enter your email address to receive the national newsletter and enter your zip code to receive your local chapter newsletter.

Click on the arrow to view various topics applicable to Crohn’s disease and ulcerative colitis.More in Resources

Read more:
Crohn’s | Colitis | IBD | Crohns & Colitis Foundation

Posted in Ulcerative Colitis | Comments Off on Crohn’s | Colitis | IBD | Crohns & Colitis Foundation

InDex Pharmaceuticals Receives Orphan-drug Designation for … – Markets Insider

Posted: at 3:44 pm

STOCKHOLM, August 9, 2017 /PRNewswire/ —

InDex Pharmaceuticals Holding AB (publ) today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

“We are pleased that the FDA has granted orphan-drug designation for cobitolimod for treatment of ulcerative colitis in children, which may provide seven years of market exclusivity in this indication on the US market,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “The decision shows the medical need for new therapeutic options for this patient population and gives InDex additional opportunities to interact with the FDA.”

Cobitolimod in brief

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct and DIMS0150.

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit http://www.indexpharma.com

For more information, contact:

Peter ZerhouniCEOPhone: +46-8-508-847-35E-mail: rel=”nofollow”>[email protected]

This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-receives-orphan-drug-designation-for-pediatric-ulcerative-colitis-in-the-us,c2323978

View original content:http://www.prnewswire.com/news-releases/index-pharmaceuticals-receives-orphan-drug-designation-for-pediatric-ulcerative-colitis-in-the-us-300501982.html

SOURCE Index Pharmaceuticals

Read more:
InDex Pharmaceuticals Receives Orphan-drug Designation for … – Markets Insider

Posted in Ulcerative Colitis | Comments Off on InDex Pharmaceuticals Receives Orphan-drug Designation for … – Markets Insider

If You Live in a City, Science Says You’re More at Risk of These Incurable Diseases – Reader’s Digest

Posted: at 3:44 pm

Inflammatory bowel disease refers to a miserable set of symptoms that dont usually get discussed in polite company. IBD is one of the common sources of stomach distressand it can be responsible for abdominal cramping, diarrhea, and bloody stool, fatigue, and weight loss. The most common sources of IBD are Crohns Disease and ulcerative colitis, and cases are on the rise, according to the Centers for Disease Control and Prevention. Now a recent study suggests that rural livingespecially during the first five years of a childs lifeprovides significant protection from these conditions.

Lead study author Eric I. Benchimol MD, PhD, and colleagues relied on health data collected during surveys of virtually all residents of the Canadian provinces of Alberta, Manitoba, Nova Scotia, and Ontario. In 2011, the provinces had a combined population of more than 19 million peopleand 45,567 of them had either Crohns Disease or ulcerative colitis.

Taras Mikhailyuk/shutterstock

Once Dr. Benchimol divided the groups into rural versus urban, he found that the incidence of IBD for country folk was 30.72 per 100,000; in cities, the rate was 33.16 per 100,000. In addition, rural patients were diagnosed at an older age than urban patients.

The study, which was conducted at the Childrens Hospital of Eastern Ontario (CHEO) Research Institute and the Canadian Gastro-Intestinal Epidemiology Consortium, (CanGIEC), and published in the American Journal of Gastroenterology, also confirmed that spending time during the first five years of life in a rural household is strongly protective against developing IBD down the road. Crunching the numbers even further, the researchers came to believe that the first year of a childs life is the most critical time for establishing that protection.

The results made sense to the researchers, who were already aware that growing up in a smaller family increases the risk of IBD (families tend to be smaller in the city than in the country). Also, children who have been exposed to farm animals at an early age are at a lower risk. The precise reason for why country living is protective against IBD is not yet clear, but the researchers believe it may have something to do with the properties of gut bacteria to which people are exposed in the country versus the city.

Originally posted here:
If You Live in a City, Science Says You’re More at Risk of These Incurable Diseases – Reader’s Digest

Posted in Ulcerative Colitis | Comments Off on If You Live in a City, Science Says You’re More at Risk of These Incurable Diseases – Reader’s Digest

How to Know if Your Bathroom Issues Are Actually Ulcerative Colitis – SELF

Posted: August 9, 2017 at 3:40 pm

When your gut is playing with games with you, it’s easy to blame it on stress or something you ate. But if you’re plagued with bathroom issues all the timeespecially diarrhea, abdominal pain, and bleedingit may be a sign of a more serious bowel disease, like ulcerative colitis.

Ulcerative colitis, or UC for short, is a form of inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers in the innermost lining of your large intestine (i.e. colon) and rectum. It can come with debilitating symptoms and even lead to life-threatening complications, so getting to a doctor when you’re experiencing symptoms is key.

IBD is characterized by chronic inflammation in your digestive tractnot to be confused with irritable bowel syndrome (IBS), which is a chronic condition that affects contractions of the muscles in your large intestine. Ulcerative colitis and Crohn’s disease are two main types of IBD that share some of the same symptoms, but one main difference is where the disease occurs: Crohn’s disease causes ulceration throughout your digestive tract, while UC is mostly contained to the colon and rectum.

Ulcerative colitis can start gradually and become worse over time and, like most diseases, cases can range from mild to severe, according to the National Institutes of Health. Most people have periods of remission (when they dont have symptoms), which can last for weeks or years, the NIH says, and periods of “flares,” or active disease.

Those can include diarrhea with blood or mucus, abdominal pain and cramping, rectal pain and bleeding, a strong urgency to go, an inability to have a bowel movement despite feeling like you need to, weight loss, fatigue, and fever. It usually shows up first as diarrhea mixed with blood as well as an urgent need to go, Ashwin Ananthakrishnan, M.D., M.P.H., a gastroenterologist at Massachusetts General Hospital who specializes in ulcerative colitis, tells SELF. Some people can experience symptoms in other parts of their body, like joint swelling and joint aches, he says.

Depending on your ulcerative colitis symptoms, the disease isn’t always easy to diagnose, especially since they can be mild at first, Darrell Gray, M.D., M.P.H., a gastroenterologist at the Ohio State University Wexner Medical Center, tells SELF. These symptoms can be subtle and representative of other things, he says. However, doctors can conduct blood tests, stool tests, and a colonoscopy to give you a proper diagnosis.

Ulcerative colitis patients can get very sick from weight loss and malnutrition, and develop anemia (low blood counts) which can cause fatigue and other issues, Dr. Ananthakrishnan says. In more severe cases, ulcerative colitis can affect a persons ability to function normally, he says. It can also put people at risk of toxic megacolon, which causes the colon to burst and can expose them to a systemic infection like sepsis, Dr. Gray says.

Ulcerative colitis can be deadly if you have a severe case that’s left untreated, Rudolph Bedford, M.D., a gastroenterologist at Providence Saint John’s Health Center in Santa Monica, California., tells SELF. Patients with more severe cases are at an increased risk of developing colon cancer and liver disease, Dr. Bedford explains.

Its possible that UC is caused by an immune system malfunction, according to the Mayo Clinic, but experts aren’t entirely sure. When your immune system tries to fight a virus or bacteria, an abnormal immune response may cause your immune system to attack the cells in your digestive tract as well. Genetics may also play a role, the Mayo Clinic says. However, they note, many people with the condition dont actually have a family history of the disease.

Ulcerative colitis can range from mild to severe, and it can impact different areas of your digestive tract. These are the main forms, per the Mayo Clinic:

Ulcerative proctitis: With this form of the condition, which tends to be the mildest, a person has inflammation in the area closest to the rectum. Rectal bleeding may be the only sign of the disease.

Proctosigmoiditis: Inflammation with this form of the disease involves a persons rectum and lower end of the colon. Symptoms can include bloody diarrhea, abdominal pain, and an inability to go despite feeling like you need to.

Left-sided colitis: This involves inflammation from the rectum, through the lower colon, and into the descending colon. In addition to bloody diarrhea and abdominal pain on the left side, a patient may also experience weight loss.

Pancolitis: This usually impacts a persons entire colon, causing bloody diarrhea that can be severe, abdominal pain, fatigue, and severe weight loss.

Acute severe ulcerative colitis: This form of colitis is rare, and it affects the entire colon. It can cause severe pain, diarrhea, bleeding, fever, and an inability to eat.

The most common treatments are oral medications called 5-aminosalicylates, often used for milder cases, Dr. Ananthakrishnan says. But for more severe cases, patients are usually given immunosuppressive medications and biologics (medications derived from human and animal genes). Surgery may also be needed in some cases, Dr. Ananthakrishnan says.

So if you’re having recurring bathroom issues with any of the above symptoms, check in with your doctor or gastroenterologist. The sooner you seek help, the sooner you can treat your symptoms. Its possible to lead a long, healthy, and comfortable life, provided you are compliant with medications and see your doctor regularly, Dr. Bedford says.

Related:

You May Also Like: I Have a Pre-Existing Condition: Real People Share Their Health Conditions

Here is the original post:
How to Know if Your Bathroom Issues Are Actually Ulcerative Colitis – SELF

Posted in Ulcerative Colitis | Comments Off on How to Know if Your Bathroom Issues Are Actually Ulcerative Colitis – SELF

InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US – PR Newswire (press release)

Posted: at 3:40 pm

“We are pleased that the FDA has granted orphan-drug designation for cobitolimod for treatment of ulcerative colitis in children, which may provide seven years of market exclusivity in this indication on the US market,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “The decision shows the medical need for new therapeutic options for this patient population and gives InDex additional opportunities to interact with the FDA.”

Cobitolimod in brief

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct and DIMS0150.

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit http://www.indexpharma.com

For more information, contact:

Peter ZerhouniCEOPhone: +46-8-508-847-35E-mail: [email protected]

This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-receives-orphan-drug-designation-for-pediatric-ulcerative-colitis-in-the-us,c2323978

View original content:http://www.prnewswire.com/news-releases/index-pharmaceuticals-receives-orphan-drug-designation-for-pediatric-ulcerative-colitis-in-the-us-300501982.html

SOURCE Index Pharmaceuticals

Link:
InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US – PR Newswire (press release)

Posted in Ulcerative Colitis | Comments Off on InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US – PR Newswire (press release)

The Crohn’s & Colitis Foundation and RMEI Medical Education’s Clinical Convergence – Business Wire (press release)

Posted: at 3:40 pm

NEW YORK–(BUSINESS WIRE)–The Clinical Convergence conference series entitled Patient and Provider Perspectives in IBD, is expanding with three new cities added in 2017. The series, a partnership between the Crohns & Colitis Foundation (the Foundation) and RMEI Medical Education (RMEI) is a continuing education initiative for clinicians who treat patients with inflammatory bowel diseases (IBD) and the patients they care for. This innovative mix of educational courses brings communities of healthcare providers and IBD patients together, for improved care and outcomes. Following the success of the 2016 series, there will be three new metro areas in 2017 and all locations now include a special workshop on shared decision-making for patient attendees.

Gastroenterologists and gastroenterology advanced practice providers (nurse practitioners and physician assistants), will engage in interactive CME sessions, while patients participate in parallel education tracks tailored to their needs. The two groups will then converge into a single session for a structured discussion on best practices for IBD patient care and shared decision-making.

The patient-provider relationship, particularly in chronic conditions like IBD, is critical that patients have a more active and participatory role in the ongoing dialogue with providers, said Laura Wingate, Senior Vice President of Education, Support & Advocacy at the Foundation. We believe this annual series can help meet the Foundations long-term goals of improving the lives of patients with IBD, by empowering them with insights on their condition, and supporting the work of their clinicians at the same time.

The 2017 series kicks off on September 9 in Kansas City, MO, followed by Austin, TX on September 16, and Pittsburgh, PA on November 18. Topics will include:

Registration is available at: http://www.RMEI.com/IBDsymposium.

The Clinical Convergence: Patient and Provider Perspectives in IBD is made possible by support from AbbVie Inc., Celgene Corporation, Salix Pharmaceuticals, and Takeda Pharmaceuticals USA.

As the healthcare delivery system in the U.S. evolves from volume-based reimbursement to a value-based model, clinicians are under increasing pressure to meet requirements for patient satisfaction scores and engagement metrics, on top of clinical outcomes, notes Dr. Jacqui Brooks, SVP of Medical Strategy at RMEI. The Clinical Convergence series meets patients and providers where they live, bringing expert faculty from leading institutions to discuss practical approaches to the complex issues in IBD care management.

Known collectively as IBD, Crohns disease and ulcerative colitis affects 1 in 200 people. They are painful, medically incurable diseases that attack the digestive system. Crohn’s disease may attack anywhere along the digestive tract, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require numerous hospitalizations and surgery. Most people develop the diseases between the ages of 15 and 35; however the incidence is increasing in children.

About the Crohn’s & Colitis Foundation

The Crohn’s & Colitis Foundation (the Foundation) is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The Foundations mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research; providing educational resources for patients and their families, medical professionals, and the public; and furnishing supportive services for those afflicted with IBD. For more information visit http://www.crohnscolitisfoundation.org, call 888-694-8872, or email [email protected].

About RMEI Medical Education

Founded in 1990, RMEI Medical Education (RMEI) is one of the longest operating medical education companies in the U.S. With an emphasis on sophisticated learner analytics for program design, delivery and assessment, RMEI works to elevate the dialogue on what makes for effective education. In designing innovative teaching modalities such as the Clinical Convergence platform for its primary therapeutic areas of focus, RMEI seeks to inspire greater collaboration within the care team and stronger commitment to patient engagement. For more information, visit http://www.rmei.com, call 856-672-3152 or email at [email protected].

Continue reading here:
The Crohn’s & Colitis Foundation and RMEI Medical Education’s Clinical Convergence – Business Wire (press release)

Posted in Ulcerative Colitis | Comments Off on The Crohn’s & Colitis Foundation and RMEI Medical Education’s Clinical Convergence – Business Wire (press release)

Page 11234..1020..»